Ratings Paxman AB

Equities

PAX

SE0009806284

Market Closed - Nasdaq Stockholm Other stock markets 11:29:37 2024-05-24 am EDT			5-day change	1st Jan Change
44.3 ^SEK	-0.23%		+10.75%	+20.38%

May. 23	Paxman AB Appoints Karen Giddings Clakely to the Board	CI
May. 23	Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company is in a robust financial situation considering its net cash and margin position.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

With an expected P/E ratio at 44.3 and 24.61 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's enterprise value to sales, at 3.81 times its current sales, is high.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
PAXMAN AB	+20.38%	78.61M	D
ABBOTT LABORATORIES	-5.56%	181B	C+
MEDTRONIC PLC	-0.11%	108B	C
BECTON, DICKINSON AND COMPANY	-6.17%	66.57B	A
DEXCOM, INC.	+2.64%	49.95B	B-
CENCORA, INC.	+6.58%	43.84B	B-
HOYA CORPORATION	+4.91%	41.71B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+21.98%	31.59B	B
TERUMO CORPORATION	+14.45%	25.3B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-5.81%	23.94B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders